Osteomimicry: How tumor cells try to deceive the bone

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 3, 2010, Pages 907-915

  Rucci, Nadia ^a   Teti, Anna ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Bone metastases; Osteomimicry; Review; Tumor cells

Indexed keywords

ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; BONE MORPHOGENETIC PROTEIN; ENDOTHELIN 1; RUNX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX2; UROKINASE; WNT PROTEIN;

BIOLOGICAL MODEL; BONE MATRIX; BONE TUMOR; BREAST TUMOR; FEMALE; HUMAN; MALE; METABOLISM; METASTASIS; OSTEOBLAST; OSTEOLYSIS; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION;

ALKALINE PHOSPHATASE; BETA 2-MICROGLOBULIN; BONE MATRIX; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BREAST NEOPLASMS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOLYSIS; PHENOTYPE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WNT PROTEINS;

EID: 77956643639     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Chambers AF, AC Groom and IC McDonald: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572 (2002) (Pubitemid 37328923)
2. Sahai E: Illuminating the metastatic process. Nat Rev Cancer 7, 131-149 (2007)
3. Grunert S, M Jechlinger, H Beug: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4, 657-665 (2003) (Pubitemid 36934968)
4. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15, 740-746 (2003) (Pubitemid 37487967)
5. Jaeger EB, RS Samant, CW Rinker-Schaeffer: Metastasis suppression in prostate cancer. Cancer Metastases Rev 20, 279-286(2001) (Pubitemid 34595271)
6. Weber MH, D Goltzman, P Kostenuik, S Rabbani, G Singh, WC Duivenvoorden, FW Orr: Mechanism of tumour metastasis to bone. Crit Rev. in Eukaryotic Gene Expression 10, 281-302 (2000)
7. Batson OV: The function of the vertebral veins and their role in the metastatic processes. Ann Intern Med 16, 38-45 (1942)
8. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889)
9. Roodman, GD: Mechanisms of Bone Metastasis. New Eng JMed 350, 1655-1664 (2004)
10. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12, 6243s-6249s (2006) (Pubitemid 44703797)
11. Coleman R, R Rubens: The clinical course of bone metastases in breast cancer. Br J Cancer 11, 336-340 (1987)
12. Sloan EK and RL Anderson: Genes involved in breast cancer metastasis to bone. Cell Mol Life Sei 59, 1491-1502 (2002) (Pubitemid 35239305)
13. Harada M, M Iida, M Yamaguchi, K Shida. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. In: Prostate cancer and bone metastasis. Eds: Kerr, Yamanaka. New York: Plenum Press (1992)
14. Yi B, PJ Williams, M Niewolna, Y Wang, T Yoneda: Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62, 917-923 (2002) (Pubitemid 34126973)
15. Koeneman KS, F Yeung and LWK Chung: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone microenvironment. The prostate 39, 246-261 (1999) (Pubitemid 29244499)
16. Yeung F, WK Law, CH Yeh, JJ Westendorf, Y Zhang, R Wang, C Kao, LW Chung: Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 277, 2468-2476 (2002) (Pubitemid 34953269)
17. Brown LF, A Papadopoulos-Sergiou, B Berse, EJ Manseau, K Tognazzi, CA Perruzzi, HF Dvorak, DR Senger: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145, 610-623 (1994) (Pubitemid 24285968)
18. Carlinfante G, D Vassilioul, O Svensson, M Wendel, D Heinegard, G Andersson: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20, 437-444 (2003) (Pubitemid 37108430)
19. Ibrahim T, I Leong, O Sanchez-Sweatman, R Khokha, J Sodek, HC Tenenbaum, B Gnass, S Cheifetz: Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 18, 253-260 (2000) (Pubitemid 32269995)
20. Waltregny D, A Bellahcene, I Van Riet, LW Fisher, M Young, P Fernandez, W Dewé, J de Levai, V Castronovo: Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90, 1000-1008(1998) (Pubitemid 28340442)
21. Waltregny D, A Bellahcene, X de Levai, B Florkin, U Weidle, V Castronovo: Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15, 834-843 (2000) (Pubitemid 30233406)
22. Li Y, PJ Cozzi. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 33, 521-527 (2007) (Pubitemid 47355340)
23. Chung LWK, A Baseman, V Assikis, HE Zhau: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urology 173, 10-20 (2005) (Pubitemid 39627663)
24. Matsubara S, Y Wada, TA Gardner, M Egawa, MS Park, CL Hsieh, HE Zhau, C Kao, S Kamidono, JY Gillenwater, LW Chung: A conditional replication-competent adenoviral vector, Ad-OC-Ela, to co target prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61, 6012-6019 (2001) (Pubitemid 32762530)
25. Zhang J, J Dai, Y Q.i., DL Lin, P Smith, C Stray horn, A Mizokami, Z Fu, J Westman, ET Keller: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107, 1235-1244(2001) (Pubitemid 32494540)
26. Holen I, PI Croucher, FC Hamdy, CL Eaton: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62, 1619-1623 (2002) (Pubitemid 34408480)
27. Kapoor P, Suva LJ, Welch D.R., Donahue HJ Osteoprotegerin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem 103, 30-41 (2007).
28. Guise TA, KS Mohammad, G Clines, EG Stebbins, DH Wong, LS Higgins, R Vessella, E Corey, S Padalecki, L Suva, JM Chirgwin: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12, 6213s-6216s(2006) (Pubitemid 44703792)
29. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27, 165-176(2001) (Pubitemid 32452017)
30. Yin JJ, K Selander, JM Chirgwin, M Dallas, BG Grubbs, R Wieser, J Massaguè, GR Mundy, TA Guise: TGFbeta signalling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103, 197-206 (1999) (Pubitemid 29053137)
31. Powell GJ, J Southby, JA Danks, RG Stillwell, JA Hayman, MA Henderson, RC Bennett, TJ Martin: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51, 3059-3061 (1991)
32. Southby J, MW Kissin, JA Danks, JA Hayman, JM Moseley, MA Henderson, RC Bennett, TJ Martin: Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 50, 7710-7716(1990)
33. Vargas SJ, MT Gillespie, GJ Powell, J Southby, JA Danks, JM Moseley, TJ Martin: Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridisation. J Bone Miner Res 7, 971-979 (1992)
34. Mancino AT, VS Klimberg, M Yamamoto, SC Manolagas, E Abe: Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100, 18-24(2001) (Pubitemid 32807701)
35. Sotiriou C, M Lacroix, L Lespagnard, D Larsimont, M Paesmans, JJ Body: Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. CancerLett 169, 87-95 (2001) (Pubitemid 32532100)
36. Park BK, H Zhang, Q Zeng, J Dai, ET Keller, T Giordano, K G.u., V Shah, L Pei, PJ Zarbo, L McCauley, S Shi, S Chen, CY Wang: NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13, 62-69 (2007) (Pubitemid 46067387)
37. Bendre M, D Gaddy, RW Nicholas, LJ Suva: Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res 415, S39-S45 (2003) (Pubitemid 37323318)
38. Kang Y, P Siegel, W Shu, M Drobnjak, SM Kakonen, G Cordon-Cardo, TA Guise, J Massaguè: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 56, 537-549 (2003) (Pubitemid 36808649)
39. Manolagas SC: Role of cytokines in bone resorption. Bone 17, 63S-67S (2006)
40. Salem AM, SF Zohny, E Abd, MM Wahab, R Hamdy. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Clin Biochem.40, 1201-1208 (2007) (Pubitemid 47570037)
41. Peyruchaud O, B Winding, I Pécheur, CM Serre, P Delmas, P Clézardin: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16, 2027-2034(2001) (Pubitemid 32995393)
42. Bellahcène A., R Bachelier, C Detry, R Lidereau, P Clézardin, V Castronovo: Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 101, 135-148 (2007) (Pubitemid 46115420)
43. Keller ET, J Zhang, CR Cooper, PC Smith, LK McCauley, KJ Pienta, RC Taichman: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 20, 333-349 (2001) (Pubitemid 34595275)
44. Coleman RE, J Vinholes, ME Abbey, OP Purohit: Double blind randomised trial of Pamidronate (Aredia) for the palliative treatment of metastatic bone disease. Proc ASCO 15, 528 (1996)
45. Shariat SF, B Andrews, WM Kattan, J Kim, TM Wheeler, KM Slawin: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58, 1008-1015 (2001) (Pubitemid 34017290)
46. Iwamura M, PA di Sant'Agnese, G Wu, CM Benning, AT Cockett, LJ Deftos, PA Abrahamsson: Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 53, 1724-1726 (1993) (Pubitemid 23127091)
47. Oyajobi BO, DM Anderson, K Traianedes, PJ Williams, T Yoneda, GR Mundy: Therapeutic efficacy of a soluble receptor activator of nucler factor-kappaB-IgG-Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61, 2572-2578(2001) (Pubitemid 32685841)
48. Zhang J, J Dai, Z Yao, Y L.u., W Dougall, ET Keller: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63, 7883-7890 (2003) (Pubitemid 37466723)
49. Kostenuik PJ, G Singh, FW Orr: Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 15, 41-52 (1997) (Pubitemid 27095151)
50. Wahl S: TGFbeta: the good, the bad, and the ugly. J Exp Med 180, 1587-1590(1994)
51. Pillay V, CR Dass, PF Choong: The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25, 33-39 (2007) (Pubitemid 46001467)
52. Achbarou A, S Kaiser, G Tremblay, LG Ste-Marie, P Brodt, D Goltzman, SA Rabbani: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54, 2372-2377 (1994) (Pubitemid 24138727)
53. Allan EH, TJ Martin: The plasminogen activator inhibitor system in bone cell function. Clin Orthop Relat Res 313, 54-63(1995)
54. Goltzman D: Mechanisms of the development of osteoblastic metastases. Cancer 80, 1581-1587 (1997) (Pubitemid 27444030)
55. Kasperk CH, I Börcsök, HU Schairer, U Schneider, PP Nawroth, FU Niethard, R Ziegler: Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 60, 368-374 (1997) (Pubitemid 27143452)
56. Guise TA, JJ Yin, KS Mohammad: Role of endothelin-1 in osteoblastic bone metastases. Cancer 97, 779-884 (2003)
57. Guise TA and KS Mohammad: Endothelins in bone cancer metastases. Cancer Treat Res 118, 197-212 (2004)
58. Nelson JB: Endothelin receptor antagonists. World J Urol 23, 19-27(2005) (Pubitemid 40425167)
59. Gross M, I Top, I Laux, J Katz, J Curran, C Tindell, D Agus: Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 13, 1979-1986 (2007) (Pubitemid 46649863)
60. Evans DB, M Thavarajah, JA Kanis: Immunoreactivity and proliferative actions of beta 2 microglobulin on human bone-derived cells in vitro. Biochem Biophys Res Commun 175, 795-803(1991)
61. Rowley DR, TD Dang, L McBride, MJ Gerders, B L.u., M Larsen: Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res 55, 781-786 (1995)
62. Karadag A, KU Ogbureke, NS Fedarko, LW Fisher: Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta 3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96, 956-965 (2004) (Pubitemid 38868142)
63. Huang WC, D W.u., Z Xie, HE Zhau, T Nomura, M Zayzafoon, J Pohl, CL Hsieh, MN Weitzmann, MC Farach-Carson, LW Chung: Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66, 9108-9116 (2006) (Pubitemid 44521130)
64. Huang WC, Z Xie, H Konaka, J Sodek, HE Zhau, LW Chung: Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65, 2303-2313(2005) (Pubitemid 40490140)
65. Zhang JH, J Tang, J Wang, W M.a., W Zheng, T Yoneda, J Chen: Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 23, 1043-1048 (2003)
66. Coppola D, M Szabo, D Boulware, P Muraca, M Alsarraj, AF Chambers, TJ Yeatman: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10, 184-190(2004) (Pubitemid 38114178)
67. Khodavirdi AC, Z Song, S Yang, C Zhong, S Wang, H W.u., C Pritchard, PS Nelson, P Roy-Burman: Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66, 883-888 (2006) (Pubitemid 43165954)
68. Jacob K, M Webber, D Benayahu, HK Kleinman: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59, 4453-4457 (1999) (Pubitemid 29418768)
69. Ducy P, R Zhang, V Geoffroy, AL Ridall, G Karsenty: Osf2/Cbfal: a transcriptional activation of osteoblast differentiation. Cell 89, 747-754 (1997) (Pubitemid 27516177)
70. Barnes GL, KE Hebert, M Kamal, A Javed, TA Einhorn, JB Lian, GS Stein, LC Gerstenfeld: Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64, 4506-4513 (2004) (Pubitemid 38856922)
71. Javed A, G Barnes, J Pratap, T Antkowiak, LC Gerstenfeld, AJ van Wijnen, JL Stein, JB Lian, GS Stein: Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. PNAS 102, 1454-1459 (2005) (Pubitemid 40209191)
72. Abe E: Function of BMPs and BMP antagonists in adult bone. Ann N Y Acad Sei 1068, 41-53 (2006) (Pubitemid 43824135)
73. Li X, X Cao: BMP signalling and skeletogenesis. Ann N Y Acad Sei 1068, 26-40 (2006)
74. Dai J, J Keller, J Zhang, Y L.u., Z Yao, ET Keller: Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65, 8274-8285 (2005) (Pubitemid 41330592)
75. Feeley BT, L Krenek, N Liu, WK Hsu, SC Gamaradt, EM Schwarz, J Huard, JR Lieberman: Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38, 154-166 (2006) (Pubitemid 43165781)
76. Buijs TJ, NV Henriquez, PGM van Overveld, G van der Horst, I Que, R Schwaninger, C Rentsch, P ten Dijke, AM Cleton-Jansen, K Driouch, R Lidereau, R Bachelier, S Vucikevic, P Clezardin, SE Papapoulos, MG Cecchini, CWGM Lowik, G van der Pluijm: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67, 8742-8751 (2007) (Pubitemid 47437450)
77. Van Hul E., J Gram, J Bollerslev, L van Wesenbeeck, D Mathysen, PE Andersen, F Vanhoenacker, W van Hul: Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome llql2-13. J Bone Miner Res 17, 1111-1117 (2002) (Pubitemid 34535150)
78. van de Wetering M, R Cavallo, D Dooijes, M van Beest, J van Es J, Y Loureiro, A Ypma, D Hursh, T Jones, A Bejsovec, M Peifer, M Mortin, H Clevers: Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88, 789-799 (1997) (Pubitemid 27164267)
79. Logan CY, R Nusse: The Wnt signaling pathway in development and disease. Ann Rev Cell Dev Biol 20, 781-810 (2004) (Pubitemid 39488658)
80. Hall CL, ET Keller: The role of Wnts in bone metastases. Cancer Metastasis Rev 25, 551-558 (2006) (Pubitemid 46074998)
81. nd, P Bialek, JD Ahn, M Starbuck, MS Patel, H Clevers, MM Taketo, F Long, AP McMahon, RA Lang, G Karsenty: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8, 751-764(2005) (Pubitemid 40585297)
82. Cheng L, RF Paterson, SD Beck, J Parks. Prostatic intraepithelial neoplasia: an update. Clin Prostate Cancer 3, 26-30 (2004) (Pubitemid 39006583)
83. Hall CL, A Bafico, J Dai, SA Aaronson, ET Keller: Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65, 7554-7560 (2005) (Pubitemid 41297224)
84. Bilezikian JP: Osteonecrosis of the jaw-do bisphosphonates pose a risk? N EnglJ Med 355, 2278-2281 (2006) (Pubitemid 44837776)
85. Lin DL, CP Tarnowski, J Zhang, J Dai, E Rhön, AH Patel, MD Morris, ET Keller: Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralises in vitro. Prostate 47, 212-221 (2001) (Pubitemid 32378373)
86. Noti JD: Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. IntJOncol 17, 1237-1243 (2000)